Bayer’s Early R&D To Get Boost After Material Sciences Sell-Off
This article was originally published in The Tan Sheet
Executive Summary
Germany’s diversified big pharma firm will become a bit more focused, with the goal of aiding its faster growing segments.
You may also be interested in...
Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did
Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.
Ahead Of Schedule, Pfizer Prepares To Set Zoetis Free In Stock Swap
The Big Pharma intends to loosen its leash on its former animal health business come June when Pfizer shareholders will be given an option to swap their shares for Zoetis stock. Meanwhile, Pfizer continues its strategy to shift its focus back to the core pharmaceutical business.
Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: